ovel gastrointestinal-mediated mechanism of action of metformi
- Conditions
- Patients with type 2 diabetes
- Registration Number
- JPRN-jRCTs051200115
- Lead Sponsor
- Sakaguchi Kazuhiko
- Brief Summary
A PET/MRI imaging protocol (PET/MRE) was developed to allow quantification of radioactivity in a fixed volume of the intestinal tract. The glucose excretion into the intestinal lumen in metformin users was approximately 1.6 g/hour, comparable to the urinary glucose excretion in SGLT2 inhibitor users.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 5
1.Patients with type 2 diabetes
2.Patients taking more than 1000 mg of metformin hydrochloride per day
3.Patients with no obvious lesions in the lower gastrointestinal tract
4.Patients who were 20 years of age or older and Under 75 years old at the time of obtaining consent
5.Patients who have given their voluntary written consent to participate in this clinical study
1.Patients with contraindications to scopolamine butylbromide
2.Patients suffering from dementia or mental illness
3.Patients with possible bowel perforation or obstruction
4.Patients with metals in the body that are not amenable to PET/MRE testing
5.Pregnant or breast feeding patients
6.Other patients who are deemed inappropriate by the investigators of this clinical study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method FDG excretion per hour into the intestinal lumen
- Secondary Outcome Measures
Name Time Method HbA1c, plasma glucose levels and various clinical parameters<br>Presence or absence of disease